ASA’s Latest Warning on Weight Management Medicine Advertising

The UK Advertising Standards Authority (ASA), alongside the MHRA and General Pharmaceutical Council (GPhC), has issued a fresh warning to businesses regarding the promotion of prescription-only and unlicensed medicines in the weight management sector.

For aesthetic clinics operating in an increasingly competitive medical weight management space, the update is a timely reminder that regulatory scrutiny around advertising is tightening further.

According to the ASA, businesses must not promote prescription-only medicines (POMs) directly or indirectly to the public, including newly licensed products or those still under regulatory review. This includes any marketing that could be interpreted as encouraging demand for a specific medicine before it is legally permitted for public advertising.

The guidance also reinforces that even indirect references—such as naming pipeline products, using category descriptors, or promoting waiting lists for specific medicines—may still breach advertising rules if they imply availability or create consumer demand.

What the regulators are focusing on

The warning highlights several key compliance risks for clinics and providers:

• Advertising or referencing prescription-only weight loss medicines to the public
• Promoting newly licensed medicines before full regulatory approval for marketing
• Using waiting lists or “early access” messaging for unlicensed or not-yet-marketable products
• Indirect references that could still be interpreted as product promotion

The ASA emphasises that prescription medicines must only be discussed in the context of a clinical consultation, not as part of public-facing marketing.

Why this matters for aesthetic clinics

For aesthetic business owners offering or planning to offer weight management services, this update is particularly important.

The line between promoting a service and inadvertently promoting a prescription product is becoming increasingly narrow. Even well-intentioned educational content or “coming soon” messaging can potentially fall foul of the rules if it is seen to generate demand for a specific medicine.

This reinforces a wider regulatory shift: clinics should focus on promoting consultations, clinical pathways and professional services, rather than any named or implied pharmaceutical product.

Industry context

This announcement forms part of a wider regulatory effort to protect consumers from inappropriate or misleading promotion of powerful prescription treatments, particularly in the rapidly expanding weight management sector.

The ASA continues to take action against online advertising that blurs the boundary between healthcare information and product promotion, especially on social media and clinic websites.

Source

This article is based on guidance published by the Advertising Standards Authority (ASA):
https://www.asa.org.uk/news/warning-on-promoting-newly-licensed-prescription-only-medicines-and-unlicensed-medicines-for-weight-management.html

Key takeaway for clinic owners

As demand for medical weight management grows, compliance is becoming a core part of clinic strategy. Ensuring your marketing remains focused on services—not specific prescription medicines—is now essential to reduce regulatory risk and maintain professional standards.